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Emerging evidence suggests cancer stem cells
CSCs) sustain neoplasms; however, little is under-
tood of the healthy cell initially targeted and the
esultant CSCs [1-3]. The most advanced understand-
ng comes from the hematologic malignancies because
f the availability of quantitative functional assays for
ormal stem cells (hematopoietic stem cells; HSCs)
nd progenitor cells (colony-forming cells), as well as
or leukemic stem cells (LSCs) and progenitor cells
acute myeloid leukemia [AML]-colony-forming
ells). Advances in the ability to identify the biological
roperties of individual human HSCs and LSCs by
sing retroviral-mediated clonal tracking coupled with
he nonobese diabetic/severe combined immunodeﬁ-
iency (NOD/SCID) mouse xenotransplantation as-
ay have been critical to progress [4-6]. These studies
emonstrated that LSCs are not functionally homo-
eneous but, like the normal HSC compartment, are
omposed of distinct hierarchically arranged LSC
lasses. Thus, the AML clone is organized as a hier-
rchy that originates from human SCID leukemia-
nitiating cells (SL-ICs), which produce AML colony-
orming units (AML-CFUs) and leukemic blasts.
oreover, similarities between SL-ICs and normal
SCs support a hypothesis that the target cell of
rigin of AML LSCs often lies within the normal stem
ell compartment, although, as noted below, under
ome circumstances LSCs could arise through the
cquisition of additional mutations in downstream
rogenitors [1,3].
LSCs hold the key to understanding the origin
nd maintenance of AML and possess biological prop-
rties that are different from the bulk of the leukemic
lones; this makes them difﬁcult to eradicate. Thus, h
B&MTlucidation of these LSC-speciﬁc properties will aid in
he development of more effective therapy that can be
argeted to the most primitive LSCs.
ORMAL HSCS
The mammalian hematopoietic system is a hier-
rchy derived from stem cells that possess extensive
elf-renewal, proliferative, and differentiative capacity.
SCs maintain the hematopoietic system throughout
ife, and stem cell regulation is a critical element in the
ontrol of normal hematopoiesis. HSCs can be con-
lusively examined only by in vivo repopulation. We
ave used repopulation of immune-deﬁcient mice to
evelop a quantitative assay for human stem cells that
ave been termed SCID-repopulating cells (SRCs). A
etailed characterization of SRCs is emerging in terms
f frequency, cell-surface phenotype, and cytokine re-
ponsiveness [3,7]. To understand the composition of
he human HSC compartment, we tracked the in vivo
ate of individual SRCs during repopulation of NOD/
CID mice by analysis of the unique clonal markers
hat were introduced with retroviral vectors [4,5]. The
ector integration site provides a marker that is stably
nherited by all progeny of an active stem cell. Analysis
f serial bone marrow aspirations from NOD/SCID
ice transplanted with transduced cord blood dem-
nstrated that the repopulation was oligoclonal, with
xtensive variability in self-renewal capacity, as well as
n the life span and proliferative capacity of individual
RC. Some clones contributed only for several weeks
fter the transplantation and disappeared, whereas
thers appeared later and persisted. Secondary re-
opulation experiments demonstrated that there was
eterogeneity in the self-renewal capacity of the trans-
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1uced SRCs. These data point to the existence of
ifferent classes of human stem cells with short-term
ST) and long-term (LT) repopulating capacity (ST-
RCs and LT-SRCs).
EUKEMIA STEM CELLS
Although cancer is often regarded as overprolif-
ration of neoplastic cells that do not differentiate
roperly, it has been known for more than a century
hat solid tumors and leukemias exhibit heterogeneity
f cellular morphology. However, morphology and
unction are difﬁcult to link, and consequently little is
nown of the cells that maintain the neoplasm. The
oncept that only a minor subpopulation of so-called
SCs is responsible for maintenance of the neoplasm
merged approximately 50 years ago. The best evi-
ence comes from the discovery that the vast majority
f AML blasts do not proliferate, and only a minor
roportion (approximately 1%) of human leukemic
ells are clonogenic progenitors (AML-CFU) [3].
owever, parallel studies of normal clonogenic pro-
enitors showed that most are not repopulating
SCs, thus calling into question whether AML-CFU
s a true LSC. Conclusive evidence for the existence of
SCs came from our identiﬁcation of a very rare
opulation of human SL-ICs (1 per 106 leukemic
lasts) that were capable of propagating AML in a
enograft transplant system we developed for LSCs
nd normal stem cells [8]. In this system, SL-ICs
enerated leukemic grafts that were highly represen-
ative of the original patient’s disease: they had iden-
ical blast morphology and dissemination proﬁles.
ell puriﬁcation, based on cell-surface markers that
nrich for normal stem and progenitor cells, demon-
trated that SL-ICs from a large number of AML
amples were highly enriched in the CD34CD38
raction and could not be found in any other fraction,
ncluding CD34CD38 cells [8-11]. Because AML-
FUs are contained in the CD34CD38 fraction,
hese studies provided functional proof that the AML
lone is organized as a hierarchy that originates from
L-ICs, which produce AML-CFUs and leukemic
lasts [8,9,12]. Normal HSCs, as measured by repopu-
ation of NOD/SCID mice, are also highly enriched
n the LinCD34CD38 fraction. We hypothesized
hat the similar cell-surface phenotype between cell
ractions highly enriched for normal HSCs and SL-
Cs from AML samples, derived from a wide diversity
f leukemic subtypes in terms of their differentiation
roperties, indicated that AML originated from the
SC pool as opposed to the committed progenitor
ool. However, one limitation of this comparison is
hat the leukemogenic process disrupts cell differen-
iation, thus making a direct link based on cell-surface
arkers between LSCs and a representative stage of L
0ormal hematopoietic development tenuous. Indeed,
ome differences between normal HSC and LSC sur-
ace-marker expression have been identiﬁed [13-16].
hus, the only comparison that is reliable must be
ased on functional stem cell properties.
The essential feature common to all stem cells is
he capacity for self-renewal upon cell division, pro-
ucing at least 1 daughter cell that possesses stem cell
roperties identical to those of the parent [17]. The
rogressive loss of self-renewal capacity is the likely
echanism underlying the existence of multipotential
urine HSCs with ST and LT repopulation capacity.
f LSCs and HSCs are related as we predict, the LSC
ool should be similarly complex; they should possess
elf-renewal machinery and the ability to also regulate
elf-renewal to create a hierarchical structure.
To determine whether SL-ICs are a homogenous
opulation of LSCs in which each member possesses
n equivalent repopulating function or whether there
s functional heterogeneity, we undertook a clonal
racking approach as outlined previously. We found
hat some clones contributed transiently, whereas oth-
rs were LT and stable, thus indicating that SL-ICs
re in fact heterogeneous and that the entire pool is
omposed of different classes of ST and LT SL-ICs
6]. The mechanism that underlies this heterogeneity
s variation of the self-renewal capacity of each SL-IC
ype. The self-renewal capacity was determined by
erforming serial transplantations and assessing
hether the clone persisted or disappeared. Some SL-
Cs persisted in secondary and tertiary mice, and this
rovided conclusive proof for the self-renewal of a
SC. In addition, some LT SL-ICs generated a tran-
ient graft in secondary mice, thus indicating that ST
L-ICs derive from LT SL-ICs. The fact that both
SC and normal HSC compartments are structured
s a hierarchy as a consequence of progressive loss in
elf-renewal capacity provides strong support for the
ypothesis that in AML, the initial target cell for
ransformation lies within the HSC compartment [3].
f course, because leukemogenesis is a multistep pro-
ess, the additional “hits” that are required could arise
n these abnormal, but “preleukemic” stem cells or in
ore downstream progenitors to result in a fully
ransformed LSC. These data show that the leukemo-
enic program does not abolish all the pathways that
egulate normal hematopoiesis at the stem cell level.
hus, the intrinsic self-renewal capacity, as well as the
ecline in self-renewal capacity (ie, regulation of self-
enewal) due to commitment processes, of HSCs tar-
eted by the initial leukemogenic event(s) continues to
unction in the resultant LSC. Indeed, the recent
nding that the stem cell–speciﬁc gene Bmi-1 plays a
ey role in the self-renewal of both normal and leu-
emic murine stem cells supports this idea [18,19].
The discovery of functional complexity in the
SC compartment has critical implications for the
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Human AML Stem Cell Compartment
Bnvestigation of cancer-speciﬁc signaling pathways and
he development of stem cell–targeted AML thera-
ies. Because cancer pathways may function differ-
ntly within each LSC subclass compared with the
ulk leukemic blasts, differential responses to a given
herapy may result. Effective therapy must target the
ighly self-renewing LT SL-ICs within a functionally
eterogeneous SL-IC pool that is responsible for ag-
ressively driving the growth and relapse of AML.
urrent AML therapies typically target proliferating
ells; however, SL-ICs are quiescent, which makes
hem poorly responsive to such agents. Future thera-
ies may be more successful if they target the altered
elf-renewal machinery of LSCs to more speciﬁcally
radicate the LSCs.
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